TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
AssigneeThe Regents of the University of California
InventorsFrank MCCORMICK, Man-Tzu WANG
Life of this patent
Estimating the term…
Abstract
The present invention provides method of treating a K-Ras-expressing cancer in a subject comprising administering to the subject a therapeutic amount of an agent that antagonizes leukemia inhibitory factor (LIF). Compositions and kits for treating a K-Ras-expressing cancer in a subject are also provided.
Claims26
A method of treating a K-Ras-expressing cancer in a subject, the method comprising administering to the subject a therapeutic amount of an agent that antagonizes leukemia inhibitory factor (LIF).
A method of treating a pancreatic cancer in a subject, the method comprising administering to the subject a therapeutic amount of an agent that antagonizes leukemia inhibitory factor (LIF).
A kit for treating a K-Ras-expressing cancer, the kit comprising:
- an agent that antagonizes leukemia inhibitory factor (LIF);
- and
- a chemotherapeutic agent.
Dependencies are inferred from the claim text.